The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

These sleep aflictions are now recognised in most cases of early dementia – this new discovery could lead to earlier detection ...

Groundbreaking research reveals potential link between cytomegalovirus (CMV) and Alzheimer's disease, offering new insights ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...

Gum disease appears to disrupt brain activity, potentially increasing a person’s risk of cognitive decline.People with ...

Electric toothbrushes can be especially helpful for older adults, as they are more effective at removing plaque and easier to ...

Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...

Our medical tools and techniques are rapidly improving but our system for delivering health care is a source of widespread ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...

Diet, exercise, brain games, even using your non-dominant hand can help prevent the onset of Alzheimer's disease.

A novel tool known as the Florey Dementia Index (FDI) predicted onset age of mild cognitive impairment or Alzheimer's disease ...

Co-lead author Leen Aljayousi, a member of Prof Ayata’s lab, added: “Such treatments could significantly slow or even reverse the progression of Alzheimer’s disease, offering hope to ...